

Corrigendum

Corrigendum to: Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden

Kirk Geale^{1,2}, Ingrid Lindberg ¹, Emma C. Paulsson¹,
E. Christina M. Wennerström^{3,4}, Anna Tjärnlund³, Wim Noel⁵, Dana Enkusson³
and Elke Theander³

Rheumatology Advances in Practice 2020.
doi:10.1093/rap/rkaa070

In the originally published version of this manuscript, an error was noted in the Conclusions section. The following sentence should read: “Ustekinumab exhibits a generally favourable treatment persistency profile in both biologic-naïve and experienced patients, while SEC exhibits favourable persistency in biologic-naïve but not in biologic-experienced patients compared with ADA” instead of “Ustekinumab exhibits a generally favourable treatment persistency profile in both biologic-naïve and experienced patients, while SEC exhibits favourable persistency in biologic-experienced but not in biologic-naïve patients compared with ADA”.

This error has now been corrected online.

¹Quantify Research, Stockholm, ²Department of Public Health and Clinical Medicine, Umeå University, Umeå, ³Janssen-Cilag AB, Solna, Sweden, ⁴Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark and ⁵Janssen Pharmaceutica NV, Beerse, Belgium
Correspondence to: Kirk Geale, Department of Public Health and Clinical Medicine, Umeå University, SE-901 87 Umeå, Sweden.
E-mail: kirk.geale@umu.se